Spinal cord injury: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• TREM2 0
• GLP-1 1
• NRF2 0
• BDNF 0
• mTOR 0
• NLRP3 0
• SIRT1 0
• STING 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Bionic Symbiosis: restoring manual Dexterity after paralysis via a multimodal cortical neuroprosthesis (BIONIC-DEXTERITY)

  Chalmers Tekniska Hogskola Aktiebolag· Goteborg, Sweden· EU contribution €2,500,000· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Magnetopyroelectric Biomedical Microrobots (PYROBOTS)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €2,490,692· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  uNreveal the rOle of SpaRtin in MitochondriA (NORMA)

  Alma Mater Studiorum - Universita di Bologna· Bologna, Italy· EU contribution €420,751· until Dec 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Clinical Evaluation of Automatic FES Calibration (AUTO-FES)

  Technische Universitaet Muenchen· Muenchen, Germany· EU contribution €150,000· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Microfabricated Scaffold Carriers of human Neural Stem Cell Therapies for the Treatment of Chronic Spinal Cord Injury (H-Neuroimplants)

  Reneurocell Therapeutics Idiotiki Kefalaiouchiki Etaireia· Irakleio, Greece· EU contribution €488,600· until Jul 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A Wireless Peripheral-Cortical Interface for Real-Time Decoding of Motor Intent to Restore Assistive Control in Tetraplegia (AxonCtrl)

  Imperial College of Science Technology and Medicine· London, United Kingdom· EU contribution €150,000· until Dec 2027

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Advanced Restorative Control for Hand Empowerment: A breakthrough neurostimulation device capable of selectively stimulate motor nerves for hand grasp recovery of patients with tetraplegia (ARCHE)

  Neurinnov· Montpellier, France· EU contribution €2,499,999· until May 2028

• European Commission (Horizon Europe) · HORIZON-JU-IA

  closed-loop IMPlantable tHerapeutic neurOmodulation systems enabled by advanced micRoelectronics and Innovative pAckaging (IMPHORIA)

  Salvia Bioelectronics Bv· Eindhoven, Netherlands· EU contribution €4,567,844· until Apr 2029· 5 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Motor Adaptation Through Complexity matching in Harmonised joint action (MATCH)

  Tilburg University- Universiteit Van Tilburg· Tilburg, Netherlands· EU contribution €217,076· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Mechanism-driven neuroprosthetics to restore hemodynamic stability in parkinsonian syndromes (HemoPARK)

  Centre Hospitalier Universitaire Vaudois· Lausanne, Switzerland· EU contribution €1,500,000· until Feb 2031

  The disease is named only in the funder's project summary, not in the title.

10 of 29 running projects, newest first. Listed amounts together: €46.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Organoids 10
• Gene Expression Profiling 25
• Sequence Analysis, RNA 2
• Proteomics 10
• Metabolomics 3
• Flow Cytometry 1
• Immunohistochemistry 27
• Liquid Biopsy 1
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 116
• Machine Learning 27
• Deep Learning 9
• Cohort Studies 58
• Genome-Wide Association Study 2

• Integrative single-cell and bulk transcriptomic analyses identify a microglia-associated NAGLU signature linked to disulfidptosis-associated transcriptional patterns after spinal cord injury.

  Front Immunol, Aug 2026

• Spinal cord regeneration deploys cell-type specific developmental and non-developmental strategies to restore neuron diversity.

  Nat Commun, Jul 2026

• GP130 Regulates Macrophage Polarization and Functional Recovery after Spinal Cord Injury in Rats: A Single-Cell RNA Sequencing Study.

  Inflammation, Jul 2026

• Glia Are Bussin': How Single-Cell and Spatial Transcriptomics Enlighten the Role of Neuroglia in Spinal Cord Injury and Regeneration.

  Glia, Jun 2026

• Decoding CNS regeneration: Insights from single-cell RNA sequencing in SCI and TBI across multiple species.

  Neuroscience, Nov 2025

• From Single-Cell Atlas to Functional Validation: Critical Next Steps for Understanding Tip Cell-Mediated Communication in the Injured Spinal Cord.

  J Cell Physiol, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.